Pirman takes the helm of the firm’s drug-discovery organization and research programs, tasked with maintaining the company’s current momentum in central nervous system therapy development. CEO Vlad Coric indicated that these leadership adjustments are designed to deepen the company's focus on human biology and translational innovation.

While Car moves to his new capacity as chief innovation officer, he will remain an executive officer within the company. Biohaven also expanded its executive team by designating Chief Legal Officer Warren Volles as an executive officer.